Cargando…
The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists
By February 2019, the Polish pharmaceutical industry, community and hospital pharmacies, wholesalers and parallel traders must all comply with the EU-wide Falsified Medicines Directive (FMD) legislation (2011/62/EU), to ensure that no medicinal product is dispensed to a patient without proper tracki...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750370/ https://www.ncbi.nlm.nih.gov/pubmed/29445453 http://dx.doi.org/10.1136/ejhpharm-2016-000970 |
_version_ | 1783289708108840960 |
---|---|
author | Merks, Piotr Swieczkowski, Damian Byliniak, Michal Drozd, Mariola Krupa, Katarzyna Jaguszewski, Milosz Brindley, David A Naughton, Bernard D |
author_facet | Merks, Piotr Swieczkowski, Damian Byliniak, Michal Drozd, Mariola Krupa, Katarzyna Jaguszewski, Milosz Brindley, David A Naughton, Bernard D |
author_sort | Merks, Piotr |
collection | PubMed |
description | By February 2019, the Polish pharmaceutical industry, community and hospital pharmacies, wholesalers and parallel traders must all comply with the EU-wide Falsified Medicines Directive (FMD) legislation (2011/62/EU), to ensure that no medicinal product is dispensed to a patient without proper tracking and authentication. Here we describe how Poland is complying with the new EU regulations, the actions that have been taken to incorporate the FMD into Polish Pharmaceutical Law and whether or not these actions are sufficient. We found that Poland is only partially compliant with the FMD and further actions need to be undertaken to fully meet the Delegated Act (DA) requirements. Moreover, there is lack of awareness in Poland about the prevalence of falsified medication and the time scale required for implementation of the DA. Based on our findings, we suggest that a public awareness campaign should be started to raise awareness of the increased number of falsified medicines in the legal supply chain and that drug authorisation systems are implemented by Polish pharmacies to support the FMD. |
format | Online Article Text |
id | pubmed-5750370 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-57503702018-02-12 The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists Merks, Piotr Swieczkowski, Damian Byliniak, Michal Drozd, Mariola Krupa, Katarzyna Jaguszewski, Milosz Brindley, David A Naughton, Bernard D Eur J Hosp Pharm Review By February 2019, the Polish pharmaceutical industry, community and hospital pharmacies, wholesalers and parallel traders must all comply with the EU-wide Falsified Medicines Directive (FMD) legislation (2011/62/EU), to ensure that no medicinal product is dispensed to a patient without proper tracking and authentication. Here we describe how Poland is complying with the new EU regulations, the actions that have been taken to incorporate the FMD into Polish Pharmaceutical Law and whether or not these actions are sufficient. We found that Poland is only partially compliant with the FMD and further actions need to be undertaken to fully meet the Delegated Act (DA) requirements. Moreover, there is lack of awareness in Poland about the prevalence of falsified medication and the time scale required for implementation of the DA. Based on our findings, we suggest that a public awareness campaign should be started to raise awareness of the increased number of falsified medicines in the legal supply chain and that drug authorisation systems are implemented by Polish pharmacies to support the FMD. BMJ Publishing Group 2018-01 2016-07-27 /pmc/articles/PMC5750370/ /pubmed/29445453 http://dx.doi.org/10.1136/ejhpharm-2016-000970 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Review Merks, Piotr Swieczkowski, Damian Byliniak, Michal Drozd, Mariola Krupa, Katarzyna Jaguszewski, Milosz Brindley, David A Naughton, Bernard D The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists |
title | The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists |
title_full | The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists |
title_fullStr | The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists |
title_full_unstemmed | The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists |
title_short | The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists |
title_sort | european falsified medicines directive in poland: background, implementation and potential recommendations for pharmacists |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750370/ https://www.ncbi.nlm.nih.gov/pubmed/29445453 http://dx.doi.org/10.1136/ejhpharm-2016-000970 |
work_keys_str_mv | AT merkspiotr theeuropeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists AT swieczkowskidamian theeuropeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists AT byliniakmichal theeuropeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists AT drozdmariola theeuropeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists AT krupakatarzyna theeuropeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists AT jaguszewskimilosz theeuropeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists AT brindleydavida theeuropeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists AT naughtonbernardd theeuropeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists AT merkspiotr europeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists AT swieczkowskidamian europeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists AT byliniakmichal europeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists AT drozdmariola europeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists AT krupakatarzyna europeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists AT jaguszewskimilosz europeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists AT brindleydavida europeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists AT naughtonbernardd europeanfalsifiedmedicinesdirectiveinpolandbackgroundimplementationandpotentialrecommendationsforpharmacists |